SUPERNUS PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Realized Gain
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Debt Securities, Available-for-sale, Realized Gain of $0 for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGain · last filed 2025-11-06
- SUPERNUS PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain for the quarter ending 2024-12-31 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain for the quarter ending 2023-12-31 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain for the quarter ending 2022-12-31 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain for fiscal 2024 was $9.00K.
- SUPERNUS PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- SUPERNUS PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain for fiscal 2022 was $14.00K, a 95.97% decline from fiscal 2021.
- SUPERNUS PHARMACEUTICALS, INC. debt securities, available-for-sale, realized gain for fiscal 2021 was $347.00K, a 92.03% decline from fiscal 2020.
| Period end | Debt Securities, Available-for-sale, Realized Gain 3 month | Debt Securities, Available-for-sale, Realized Gain 6 month | Debt Securities, Available-for-sale, Realized Gain 9 month | Debt Securities, Available-for-sale, Realized Gain 12 month |
|---|---|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $9.00K 10-K · filed 2025-02-25 | ||
| 2024-09-30 | $9.00K 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $0.00 derived: sum of 2 quarters · filed 2025-02-25 | $0.00 10-K · filed 2025-02-25 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $0.00 10-Q · filed 2024-11-04 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.00K derived: sum of 2 quarters · filed 2025-02-25 | $14.00K 10-K · filed 2025-02-25 | |
| 2022-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $14.00K 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $13.00K 10-Q · filed 2023-08-08 | |||
| 2021-12-31 | $347.00K 10-K · filed 2023-03-09 | |||
| 2020-12-31 | $4.35M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |